|
Q3 2024
|
162 |
92,461 |
AAPL, COST, GLD, GDX
|
13F-HR
|
11/5/2024 |
000139834424019972 |
|
Q2 2024
|
167 |
93,860 |
AAPL, COST, GLD, GDX
|
13F-HR
|
8/5/2024 |
000139834424013722 |
|
Q1 2024
|
170 |
93,756 |
AAPL, TLT, GLD, COST
|
13F-HR
|
5/9/2024 |
000139834424009058 |
|
Q4 2023
|
172 |
91,251 |
AAPL, TLT, FIBK, GLD
|
13F-HR
|
2/5/2024 |
000139834424002094 |
|
Q3 2023
|
179 |
85,101 |
AAPL, TLT, GLD, BNDD
|
13F-HR
|
11/13/2023 |
000139834423020528 |
|
Q2 2023
|
175 |
89,362 |
AAPL, TLT, BNDD, GLD
|
13F-HR
|
8/1/2023 |
000139834423013867 |
|
Q1 2023
|
166 |
85,451 |
AAPL, TLT, GLD, FIBK
|
13F-HR
|
5/10/2023 |
000139834423009385 |
|
Q4 2022
|
163 |
80,294 |
AAPL, FIBK, TLT, SHY
|
13F-HR
|
2/2/2023 |
000139834423001917 |
|
Q3 2022
|
168 |
70,327 |
AAPL, FIBK, TLT, BNDD
|
13F-HR
|
11/14/2022 |
000139834422021954 |
|
Q2 2022
|
181 |
77,426 |
AAPL, TLT, FIBK, BNDD
|
13F-HR
|
8/1/2022 |
000139834422014470 |
|
Q1 2022
|
186 |
84,540 |
AAPL, TLT, BNDD, FIBK
|
13F-HR
|
5/9/2022 |
000139834422009087 |
|
Q4 2021
|
302 |
119,170 |
AAPL, FIBK, ITB, XLK
|
13F-HR
|
2/11/2022 |
000139834422002726 |
|
Q3 2021
|
254 |
120,614 |
AAPL, FIBK, GDX, XLV
|
13F-HR
|
11/4/2021 |
000139834421020918 |
|
Q2 2021
|
308 |
129,376 |
AAPL, FIBK, GDX, AMD
|
13F-HR
|
8/10/2021 |
000139834421015831 |
|
Q1 2021
|
291 |
113,503 |
AAPL, FIBK, GDX, XLV
|
13F-HR
|
5/7/2021 |
000139834421009952 |
|
Q4 2020
|
231 |
115,536 |
AAPL, FIBK, GDX, XSD
|
13F-HR
|
1/29/2021 |
000139834421001780 |
|
Q3 2020
|
208 |
111,261 |
AAPL, FIBK, EW, GDX
|
13F-HR
|
10/28/2020 |
000139834420020952 |
|
Q2 2020
|
200 |
100,108 |
AAPL, FIBK, EW, GDX
|
13F-HR
|
8/11/2020 |
000139834420015473 |
|
Q1 2020
|
179 |
71,029 |
AAPL, FIBK, EW, PFF
|
13F-HR
|
5/6/2020 |
000139834420009561 |
|
Q4 2019
|
183 |
105,971 |
FIBK, AAPL, EW, GDX
|
13F-HR
|
2/3/2020 |
000139834420002016 |
|
Q3 2019
|
194 |
85,150 |
AAPL, EDWARDS LIFESCIENCES CORP, CARA THERAPEUTICS INC, KL
|
13F-HR
|
11/12/2019 |
000139834419019620 |
|
Q2 2019
|
260 |
83,757 |
EDWARDS LIFESCIENCES CORP, AAPL, CARA THERAPEUTICS INC, XLV
|
13F-HR
|
8/12/2019 |
000110465919045238 |
|
Q1 2019
|
276 |
74,858 |
EDWARDS LIFESCIENCES CORP, AAPL, XLV, TLT
|
13F-HR
|
5/6/2019 |
000110465919027125 |
|
Q4 2018
|
337 |
52,017 |
AAPL, EDWARDS LIFESCIENCES CORP, XLV, PFF
|
13F-HR
|
2/5/2019 |
000110465919005766 |
|
Q3 2018
|
346 |
99,459 |
AAPL, SCHX, NVDA, SCHM
|
13F-HR
|
10/31/2018 |
000110465918065028 |
|
Q2 2018
|
320 |
95,334 |
AAPL, SCHX, NVDA, MU
|
13F-HR
|
8/8/2018 |
000110465918050414 |
|
Q1 2018
|
311 |
87,203 |
AAPL, MO, SCHX, NVDA
|
13F-HR
|
5/3/2018 |
000110465918030196 |
|
Q4 2017
|
312 |
88,283 |
MO, AAPL, CELG, VGR
|
13F-HR
|
1/31/2018 |
000110465918005339 |
|
Q3 2017
|
276 |
84,534 |
MO, CELG, AAPL, BTI
|
13F-HR
|
11/7/2017 |
000110465917066594 |
|
Q2 2017
|
268 |
87,222 |
MO, CELG, RAI, FIBK
|
13F-HR
|
7/19/2017 |
000110465917045724 |
|
Q1 2017
|
267 |
80,807 |
MO, CELG, RAI, FIBK
|
13F-HR
|
4/19/2017 |
000110465917024515 |
|
Q4 2016
|
258 |
94,945 |
NKE, MO, CELG, RAI
|
13F-HR
|
1/17/2017 |
000110465917002520 |
|
Q3 2016
|
238 |
78,201 |
MO, CELG, RAI, FIBK
|
13F-HR
|
11/7/2016 |
000110465916155167 |
|
Q2 2016
|
224 |
76,486 |
MO, RAI, CELG, CORE
|
13F-HR
|
7/28/2016 |
000110465916134970 |
|
Q1 2016
|
238 |
74,126 |
MO, CELG, RAI, AAPL
|
13F-HR
|
4/28/2016 |
000110465916115338 |
|
Q4 2015
|
236 |
79,516 |
MO, CELG, RAI, CORE
|
13F-HR
|
2/1/2016 |
000110465916092803 |
|
Q3 2015
|
233 |
77,868 |
MO, CELG, RAI, AAPL
|
13F-HR
|
10/22/2015 |
000110465915072172 |
|
Q2 2015
|
259 |
88,484 |
MO, CELG, AAPL, GILD
|
13F-HR
|
7/29/2015 |
000110465915054193 |
|
Q1 2015
|
243 |
81,702 |
MO, CELG, AAPL, RAI
|
13F-HR
|
5/5/2015 |
000110465915034066 |
|
Q4 2014
|
267 |
76,989 |
MO, CELG, AAPL, PM
|
13F-HR
|
2/17/2015 |
000110465915011163 |